Fragment Screening: Save Time And Sample With Spectral Shift Technology

Fragment-based drug discovery offers powerful potential, but common screening methods like SPR, DSF, and NMR present significant hurdles. Issues like low sensitivity to small fragments, high false-positive rates, and prohibitive equipment costs can hinder progress, making it tough to identify promising hits efficiently and affordably.

Discover how Dianthus with Spectral Shift technology provides a breakthrough solution. This mass-independent, in-solution platform offers faster, less expensive screening with reliable hit rates and accurate affinity measurements, even using minimal sample amounts. See how it identified micromolar affinity hits with a 75% lower false-positive rate than DSF and screened over 1,600 compounds rapidly.

Watch the video now to learn more about optimizing your fragment screening process.